更新于：2024-06-19
Sodium Picosulfate Hydrate
匹可硫酸钠
更新于：2024-06-19
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1979-08-27), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C18H15NNa2O8S2 |
InChIKeyGNCMLBKBMBXVMB-UHFFFAOYSA-N |
CAS号10040-45-6 |
关联
36
项与 匹可硫酸钠 相关的临床试验Efficacy and Safety of the single oral dose method of the sodium picosulfate plus magnesium citrate for the preparation in colonoscopy
Bladder and Bowel Dysfunction in Children
Improved Bowel Cleansing Method for Colonoscopy Based on High Risk Population of Bowel Preparation#a Single-center,Endoscopist-blinded Randomized Controlled Trial
100 项与 匹可硫酸钠 相关的临床结果
登录后查看更多信息
100 项与 匹可硫酸钠 相关的转化医学
登录后查看更多信息
100 项与 匹可硫酸钠 相关的专利（医药）
登录后查看更多信息
298
项与 匹可硫酸钠 相关的文献（医药）2024-04-01Revista espanola de enfermedades digestivas
1-L polyethylene glycol + ascorbic acid versus sodium picosulfate + magnesium citrate bowel preparations for colonoscopy: effectiveness and safety.
Article
作者: Galera Ródenas, Ana Belén ; Pérez Arellano, Elena ; Rodríguez García, M ª Isabel ; de la Morena Madrigal, Emilio ; Flores de Miguel, Álvaro
BACKGROUND:
adequate bowel preparation is crucial for the protective effect of colonoscopy. Commonly used preparation regimens like polyethylene glycol (PEG) or sodium picosulfate with magnesium citrate (SPMC) have shown similar results in clinical trials, but low-volume PEG + ascorbic acid (1-L PEG + ASC) versus SPMC have never been compared in a real-life setting.
AIM:
to evaluate the effectiveness and safety of 1-L PEG + ASC versus SPMC in a real-life setting for the overall population, for patients aged ≥ 65 years, and males versus females.
METHODS:
out-patients aged ≥ 18 years who underwent colonoscopy for any indication were randomly assigned to the 1-L PEG + ASC or SPMC group. Using the Boston Bowel Preparation Scale (BBPS), the primary endpoints were the bowel cleansing success of the overall colon and right colon, as well as high-quality (HQ) cleansing. Furthermore, the effectiveness and safety outcomes for age groups and males versus females were compared.
RESULTS:
1-L PEG + ASC showed significantly better bowel cleansing success than SPMC. Particularly remarkable is the HQ cleansing reached with 1-L PEG + ASC compared with SPMC (55.5 % versus 25.4 % in the overall colon, and 58.7 % versus 27.2 % in the right colon). 1-L PEG + ASC was equally effective for men and women while SPMC showed significant differences between genders (men had worse bowel cleansing). Age did not affect the cleansing effectiveness. 1-L PEG + ASC versus SPMC showed significant differences in tolerance and safety; women also had significantly worse tolerance than men for both solutions, but these did not affect the quality of bowel cleansing.
CONCLUSIONS:
in our real-life setting, 1-L PEG + ASC offered better adequate and HQ bowel cleansing than SPMC, achieving excellent cleansing quality, regardless of gender or tolerance.
2023-08-01Techniques in coloproctology
An evaluation of a novel bowel preparation regimen and its effect on the utility of colon capsule endoscopy: a prospective cohort study with historical controls
Article
作者: Watson, A J M ; Macleod, C ; Oliphant, R ; Richards, C
BACKGROUND:
The aim of this study was to evaluate the efficacy of a novel bowel preparation and booster regimen for colon capsule endoscopy (CCE) using macrogol, phospho-soda and gastrografin, compared with a control regimen consisting of polyethylene glycol and sodium picosulfate.
METHODS:
This was a prospective cohort study using historical controls. Symptomatic patients undergoing CCE between 11/07/2021 and 21/12/2021 using the novel regimen were included. Symptomatic patients who underwent CCE in the ScotCap evaluation using the control regimen were used as historical controls. We measured the rate of complete test (visualisation of the whole colon and rectum), adequate bowel preparation, successful test (complete and adequate bowel preparation) and need for further test following CCE. The rate of adverse events was also collected.
RESULTS:
Patients undergoing CCE using the new and control regimen were 200 and 316, respectively. The median age, age range and proportion of female patients in the new and control regimen cohorts was 61 vs 60 years, 16-86 vs 20-83 years, and 60.5% vs 56.6%. The rate of complete test, adequate bowel reparation and successful test for the new and control regimen was 69% vs 72.2%, 86.6% vs 80.7% and 60.5% vs 65.8%. Comparing the new and control regimen, 39.5% vs 37.3% of patients required no test following CCE, 26% vs 32.6% required a colonoscopy, 31.5% vs 21.5% required a flexible sigmoidoscopy and 3% vs 2.9% required a computed tomography colonogram. No adverse events were reported using the new regimen compared to 2 (0.6%) in the control group.
CONCLUSIONS:
The rate of adequate bowel preparation has improved following the introduction of a new regimen. However, further work is needed to increase the complete test rate. A significant proportion of patients continue to avoid colonoscopy following CCE.
2023-07-01Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
Split‐dose versus day‐before regimen of sodium picosulfate plus magnesium citrate for bowel cleansing before colonoscopy in children: Randomized controlled trial
Article
作者: Parisi, Pasquale ; Lucchini, Livia ; Furio, Silvia ; Evangelisti, Melania ; Felici, Enrico ; Strisciuglio, Caterina ; Mennini, Maurizio ; Zenzeri, Letizia ; Di Nardo, Giovanni ; Quatrale, Giovanna ; Massolo, Anna Claudia ; Piccirillo, Marisa ; Hassan, Cesare
Objectives:
Polyethylene glycol (PEG) split‐dose regimen is recommended as the option of choice for colon preparation before colonoscopy in children and adults. Sodium picosulfate plus magnesium citrate (SPMC) is equally effective but better tolerated than PEG for bowel preparation before colonoscopy in children. The aim of this study was to assess the superiority of SPMC split‐dose regimen compared with SPMC day‐before regimen for bowel cleansing before colonoscopy in children.
Methods:
This was a multicenter, randomized, single‐blind study. Pediatric inpatients undergoing colonoscopy received SPMC either in the day‐before dosing or in split dosing. Overall bowel cleansing was assessed using the Boston Bowel Preparation Scale (BBPS) and was rated as successful when BBPS was ≥6. Patient tolerability, acceptability, and compliance were recorded.
Results:
The rate of successful cleansing level was significantly higher in the split‐dose group than in the day‐before group (P < 0.001). The BBPS scores were significantly higher in the split‐dose group than in the day‐before group for the whole colon (P < 0.001), the right colon (P < 0.001) and transverse colon (P < 0.001). Patient acceptability was better in the split‐dose group (P = 0.0003; P = 0.005). The percentage of children needing nasogastric tube placement was better in the split‐dose group (P = 0.007).
Conclusions:
The split‐dose regimen of SPMC was superior to the day‐before regimen in terms of successful colon cleansing and acceptability.
100 项与 匹可硫酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 造影剂 | 日本 | 1992-07-01 | |
| 肠道准备 | 日本 | 1992-03-27 | |
| 便秘 | 日本 | 1979-08-27 | |
| 便秘 | 日本 | 1979-08-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胃肠道疾病 | 临床3期 | 法国 | 2014-11-01 | |
| 胃肠道疾病 | 临床3期 | 德国 | 2014-11-01 | |
| 胃肠道疾病 | 临床3期 | 荷兰 | 2014-11-01 | |
| 弥漫性大B细胞淋巴瘤 | 临床3期 | 日本 | 2014-09-01 | |
| 功能性便秘 | 临床3期 | 中国 | 2011-09-16 | |
| 药用辅料 | 临床3期 | 美国 | 2010-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 862 | Standard dosing | 鹽窪鑰築鹽壓鬱範憲齋(膚淵壓遞齋網積鹽壓襯) = 選鑰遞願糧膚網夢鹹獵 鹹選襯鬱憲鏇遞蓋選築 (網獵壓構願願願醖網糧 ) | - | 2014-08-01 | |
Split dosing | 鹽窪鑰築鹽壓鬱範憲齋(膚淵壓遞齋網積鹽壓襯) = 鏇廠淵築艱襯醖積選顧 鹹選襯鬱憲鏇遞蓋選築 (網獵壓構願願願醖網糧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用